GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Gross Margin %

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Gross Margin % : 92.36% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Vanda Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $41.8 Mil. Vanda Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $45.3 Mil. Therefore, Vanda Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 92.36%.


The historical rank and industry rank for Vanda Pharmaceuticals's Gross Margin % or its related term are showing as below:

VNDA' s Gross Margin % Range Over the Past 10 Years
Min: 78.66   Med: 89.92   Max: 96.84
Current: 92.32


During the past 13 years, the highest Gross Margin % of Vanda Pharmaceuticals was 96.84%. The lowest was 78.66%. And the median was 89.92%.

VNDA's Gross Margin % is ranked better than
88.98% of 735 companies
in the Biotechnology industry
Industry Median: 59.43 vs VNDA: 92.32

Vanda Pharmaceuticals had a gross margin of 92.36% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Vanda Pharmaceuticals was 0.60% per year.


Vanda Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Vanda Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Gross Margin % Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.22 90.59 90.46 90.45 92.32

Vanda Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.33 92.36 92.40 92.11 92.36

Competitive Comparison of Vanda Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Vanda Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Gross Margin % falls into.



Vanda Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Vanda Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=177.8 / 192.64
=(Revenue - Cost of Goods Sold) / Revenue
=(192.64 - 14.796) / 192.64
=92.32 %

Vanda Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=41.8 / 45.271
=(Revenue - Cost of Goods Sold) / Revenue
=(45.271 - 3.46) / 45.271
=92.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Vanda Pharmaceuticals  (NAS:VNDA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Vanda Pharmaceuticals had a gross margin of 92.36% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Vanda Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341